Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
31 participants
INTERVENTIONAL
2018-09-19
2020-03-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methylphenidate is indicated at high dose (1 mg/kg/day) in children having attention deficit and hyperactivity disorder (ADHD) and remains the best cognitive enhancer drug at lower dose. However, there is no proof of efficacy with chronic administration, outside ADHD, and concern remains about long-term cardiac and vascular risks in elderly and particularly in population with vascular risk factors and drug abuse in young people. Moreover, the effect appears to be very limited at the very advanced stage of dementia, for which the neuronal plasticity is too reduced to expect a benefit of training.
Taken all together, we sought to develop a new paradigm of association of both pharmacological and non-pharmacological procedure to enhance the neuronal plasticity in order to expect a persistent effect on slight to mild cognitive disorders with benefit on ecological test (i.e. driving). Finally, short-term treatment would reduce the safety concerns.
The concept will be to prove that low dose of methylphenidate associated with active cognitive training during 6 weeks can improve the cognitive function in healthy aged volunteers with a persistent effect at 3 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment
NCT02180529
A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.
NCT03811847
Dopaminergic Modulation of Cognition and Psychomotor Function
NCT01218425
Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study
NCT02326038
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
NCT02951754
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Methylphenidate and structured cognitive training
Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
Methylphenidate
Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
CogniPlus software
Structured cognitive training with CogniPlus software, twice per week during 6 weeks
Placebo and structured cognitive training
Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
Placebo
Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
CogniPlus software
Structured cognitive training with CogniPlus software, twice per week during 6 weeks
Methylphenidate and pseudo cognitive training
Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
Methylphenidate
Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
Pseudo cognitive training
Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
Placebo and pseudo cognitive training
Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
Placebo
Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
Pseudo cognitive training
Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methylphenidate
Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
Placebo
Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
CogniPlus software
Structured cognitive training with CogniPlus software, twice per week during 6 weeks
Pseudo cognitive training
Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Absence of cognitive impairment affecting autonomy (scores on the dementia scale of Mattis\> 130 and the IADL = 4)
* Right-handed participant
* Subjects holding driving license B and continuing a driving activity
* Affiliate or beneficiary of a social security scheme
* Subject having signed informed consent
* Subject having agreed to be registered on the National File of Healthy Volunteers
* Patient willing to comply with all procedures of the study and its duration
* No planned changes in lifestyle (nutritional and physical, social interactions) during the life of the protocol
Exclusion Criteria
* Subject simultaneously participating in another clinical trial or in an exclusion period.
* Subject under tutelage or curatelle.
* Subject during breastfeeding or pregnancy.
* Subject not sufficiently fluent in the French language to understand the instructions necessary to carry out the cognitive tests.
* Subject with uncorrected visual pathology or motor pathology (orthopedic example) likely to interfere with the passing of tests.
* Subject with dependencies pre-existing to medicines, drugs or alcohol.
* Presence of contraindications to MRI: Claustrophobia, Anxiety crisis, Morphotype not allowing access to MRI, metal implant (eg a pacemaker), surgical clips Ferromagnetic, orbital or brain metallic foreign bodies).
* Hypersensitivity to methylphenidate or any other constituents of the product.
* Subject with a personal and / or family history of motor tics and Gilles de la Tourette syndrome.
* Subjects with a previous psychiatric history (based on the semi-structured psychiatric interview with the MINI of DSM IV adapted to DSM V): state, severe depression, severe generalized anxiety, anorexia nervosa or anorexic disorders, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic personality disorder or borderline disorder. Dysthymia and an isolated history of depression do not constitute an exclusion criterion.
* Subjects consuming one or more psychotropic drugs or related products (antidepressants, antipsychotics, antiepileptic drugs, daily use of benzodiazepine anxiolytics or other anxiolytics, vesperal hypnotic intake). A history of taking point hypnotics is not a criterion of exclusion. However, there should be no regular and regular intake in the previous 3 months and less than once a week (ideally, lack of intake would be desirable but would considerably limit the potential for inclusion). They will be asked not to change their habits during the study period.
* Subjects with dysthyroidism or thyrotoxicosis
* Subjects with pre-existing cardiovascular disorders including severe hypertension, heart failure, occlusive arterial disease, angina pectoris, congenital heart disease with hemodynamic repercussions, cardiomyopathy, myocardial infarction, arrhythmias and channelopathies
* Subject with angle-closure glaucoma.
* Significant abnormalities on MRI and EEG according to the investigator's judgment
* Presence of untreated hypertension discovered during screening
* Subject with pheochromocytoma
* Pre-existing cerebrovascular disorders, cerebral aneurysm, vascular abnormalities, including vasculitis or stroke in the subject
* Subjects with hepatic and renal insufficiency
* Obese subject according to WHO classification (BMI\> 30)
* Presence of one of the following treatments that cannot be stopped for a period corresponding to 5 half-lives before inclusion: selective and non-selective MAOIs (nialamide and iproniazide, selegiline), other indirect sympathomimetics (phenylpropanolamine, pseudoephedrine, Phenylephrine), halogenated volatile anesthetics, guanethidine and related compounds.
* Treatment with alpha sympathomimetics (oral and / or nasal route) (etilefrin, midodrine, naphazoline, oxymetazoline, tetryzoline, tuaminoheptane, tymazoline), opiates and morphine derivatives. These concomitant treatments are contraindicated at baseline and throughout the study period.
* Subject with leukopathy classified ≥2 on the Fazekas scale
55 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Devos, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Roger Salengro, CHU
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-005131-32
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2015_81
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.